<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">129</article-id><article-id pub-id-type="doi">10.15789/2220-7619-2013-3-213-216</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">MODERN LABORATORY APPROACHES IN THE DIAGNOSIS OF CMV INFECTION IN IMMUNOCOMPROMISED PATIENTS</article-title><trans-title-group xml:lang="ru"><trans-title>СОВРЕМЕННЫЕ ПОДХОДЫ К ЛАБОРАТОРНОЙ ДИАГНОСТИКЕ ЦИТОМЕГАЛОВИРУСНОЙ ИНФЕКЦИИ У ИММУНОКОМПРОМЕТИРОВАННЫХ ПАЦИЕНТОВ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Padalko</surname><given-names>E. Iu.</given-names></name><name xml:lang="ru"><surname>Падалко</surname><given-names>Е. Ю.</given-names></name></name-alternatives><address><country country="BE">Belgium</country></address><bio xml:lang="en"><p/><p/><p/><p>PhD, Chief, Laboratory of Clinical Virology, Ghent University Hospital; Professor of Virology, Hasselt University</p></bio><bio xml:lang="ru"><p/><p/><p/><p>руководитель лаборатории клинической биологии и руководитель лаборатории клинической вирусологии и молекулярной диагностики, Госпиталь Университета г. Гента, профессор вирусологии факультета медицины и биомедицинской науки, Университет Хасалта </p></bio><email>okubar@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Ghent University Hospital, Ghent</institution></aff><aff><institution xml:lang="ru">Госпиталь Университета г. Гента, Гент</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-07-07" publication-format="electronic"><day>07</day><month>07</month><year>2013</year></pub-date><volume>3</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>213</fpage><lpage>216</lpage><history><date date-type="received" iso-8601-date="2014-07-07"><day>07</day><month>07</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-07-07"><day>07</day><month>07</month><year>2014</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Padalko E.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Падалко Е.Ю.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Padalko E.I.</copyright-holder><copyright-holder xml:lang="ru">Падалко Е.Ю.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/129">https://iimmun.ru/iimm/article/view/129</self-uri><abstract xml:lang="en"><p/><p/><p/><p><bold>Abstract.</bold> High susceptibility of immunocomromised human to infection (especially transplant recipients) is influenced by poor ability to combat it due to impaired cellmediated immunity plus high vulnerability to perturbations in the environment. Special considerations regarding infection in transplant recipients and particular approaches in laboratory diagnostics are based on profound analysis of the nature of viral infection in this population. In this article the modern knowledge about viral infections and laboratory diagnostic methods, particularly regarding CMV infection, in immunocompromised patients are discussed. </p></abstract><trans-abstract xml:lang="ru"><p/><p/><p/><p><bold>Резюме. </bold>Высокая восприимчивость к инфекциям иммунокомпрометированных пациентов (в частности реципиентов при пересадке органов), обусловлена уязвимостью иммунной системы таких лиц к факторам внешней и внутренней среды, что требует формирования специальных подходов в лабораторной диагностике, основанной на глубоком и всестороннем понимании специфики вирусных инфекций у такой популяции пациентов. В рамках данной работы рассмотрены современные представления о течении инфекций, и, в частности, инфекции цитомегаловирусной природы у пациентов с пониженным иммунитетом, и даны объективные ориентиры для лабораторной диагностики этой инфекции. </p></trans-abstract><kwd-group xml:lang="en"><kwd>immunocomromised patients</kwd><kwd>viral infection</kwd><kwd>cytomegalovirus (CMV)</kwd><kwd>laboratory diagnostics.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>иммунокомпрометированные пациенты</kwd><kwd>вирусные инфекции</kwd><kwd>цитомегаловирус (CMV)</kwd><kwd>лабораторная диагностика.</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Baldanti F., Lilleri D., Gerna G. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol. Oncol., 2008, vol. 26 (3), pp. 123–130.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood., 2009, vol. 113 (23), pp. 5711–5719.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N. Engl. J. Med., 1998, vol. 338 (24), pp. 1741–1751.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Gerna G., Baldanti F., Lilleri D., Parea M., Torsellini M., Castiglioni B., Vitulo P., Pellegrini C., Viganò M., Grossi P., Revello M.G. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation, 2003, vol. 15;75 (7), pp. 1012–1019.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Griffiths P., Whitley R., Snydman D.R., Singh N., Boeckh M.; International Herpes Management Forum. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes, 2008, vol. 15 (1), pp. 4–12.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Koidl C., Bozic M., Marth E., Kessler H.H. Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma? J. Virol. Methods, 2008, vol. 154 (1–2), pp. 210–212.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Snydman D.R., Allen U., Humar A.; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation, 2010, vol. 89 (7), pp. 779–795.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 2000, vol. 356 (9230), pp. 645–649.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Linden P.K. Approach to the immunocompromised host with infection in the intensive care unit. Infect. Dis. Clin. North Am., 2009, vol. 23 (3), pp. 535–556.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Mañez R., St George K., Linden P., Martin M., Kusne S., Grossi P., Ho M., Rinaldo C. Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J. Clin. Microbiol., 1994, vol. 32 (11), pp. 2655–2659.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., Pescovitz M.D.; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant., 2004, vol. 4 (4), pp. 611–620.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Razonable R.R., Emery V.C.; 11th Annual Meeting of the IHMF [International Herpes Management Forum]. Management of CMV infection and disease in transplant patients. 27–29 February 2004. Herpes, 2004, vol. 11 (3), pp. 77–86.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm., 2005, vol. 15;62 (8 suppl. 1), pp. S7–13.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Riise G.C., Andersson R., Bergström T., Lundmark A., Nilsson F.N., Olofsson S. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest, 2000, vol. 118 (6), pp. 1653–1660.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Seed C.R., Piscitelli L.M., Maine G.T., Lazzarotto T., Doherty K., Stricker R., Stricker R., Iriarte B., Patel C. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion, 2009, vol. 49 (1), pp. 134–145.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Tang W., Elmore S.H., Fan H., Thorne L.B., Gulley M.L. Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn. Mol. Pathol., 2008, vol. 17 (3), pp. 166–173.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.	Weber B., Fall E.M., Berger A., Doerr H.W. Screening of blood donors for human cytomegalovirus [HCMV] IgG antibody with an enzyme immunoassay using recombinant antigens. J. Clin. Virol., 1999, vol. 14 (3), pp. 173–181.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.	Westall G.P., Michaelides A., Williams T.J., Snell G.I., Kotsimbos T.C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis., 2004, vol. 190 (6), pp. 1076–1083.</mixed-citation></ref></ref-list></back></article>
